Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an open French multicentre randomized study

Antoine Broustet , Josy Reiffers , Gérald Marit , Denis Fiere , Jérôme Jaubert , Jacqueline Reynaud , Jacques Pris , Philippe Bernard , Christine Charrin , Zong Qi Wen , Marie Françoise Berteas , Nicole Dastugue , Yolaine Parlier
{"title":"Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an open French multicentre randomized study","authors":"Antoine Broustet ,&nbsp;Josy Reiffers ,&nbsp;Gérald Marit ,&nbsp;Denis Fiere ,&nbsp;Jérôme Jaubert ,&nbsp;Jacqueline Reynaud ,&nbsp;Jacques Pris ,&nbsp;Philippe Bernard ,&nbsp;Christine Charrin ,&nbsp;Zong Qi Wen ,&nbsp;Marie Françoise Berteas ,&nbsp;Nicole Dastugue ,&nbsp;Yolaine Parlier","doi":"10.1016/0277-5379(91)90558-U","DOIUrl":null,"url":null,"abstract":"<div><p>In order to compare the effects of interferon versus hydroxyurea for the treatment of chronic myelogenous leukaemia (CML), 58 CML patients, having received no previous treatment, were randomized into two treatment groups (hydroxyurea or interferon) for an open multicentre study from 1 May 1987 until 1 July 1990. Fifty patients were evaluable: 24 in the interferon group and 26 in the hydroxyurea group. Haematological response was obtained in <span><math><mtext>16</mtext><mtext>24</mtext></math></span> interferon-treated patients and <span><math><mtext>23</mtext><mtext>26</mtext></math></span> hydroxyurea patients. Failure to obtain haematological remissions occurred in eight of 24 interferon-treated patients and in three of 26 hydroxyurea patients. Four interferon-treated patient failures and one hydroxyurea-treated failure were due to drug intolerance. Progression occurred in one interferon-treated patient and in three patients given hydroxyurea. Fourteen of 16 patients in the interferon group and <span><math><mtext>17</mtext><mtext>23</mtext></math></span> in the hydroxyurea group continue on study and show no progression.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S18-S21"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90558-U","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190558U","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

Abstract

In order to compare the effects of interferon versus hydroxyurea for the treatment of chronic myelogenous leukaemia (CML), 58 CML patients, having received no previous treatment, were randomized into two treatment groups (hydroxyurea or interferon) for an open multicentre study from 1 May 1987 until 1 July 1990. Fifty patients were evaluable: 24 in the interferon group and 26 in the hydroxyurea group. Haematological response was obtained in 1624 interferon-treated patients and 2326 hydroxyurea patients. Failure to obtain haematological remissions occurred in eight of 24 interferon-treated patients and in three of 26 hydroxyurea patients. Four interferon-treated patient failures and one hydroxyurea-treated failure were due to drug intolerance. Progression occurred in one interferon-treated patient and in three patients given hydroxyurea. Fourteen of 16 patients in the interferon group and 1723 in the hydroxyurea group continue on study and show no progression.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
羟基脲对抗干扰素α -2b治疗慢性髓性白血病:一项开放的法国多中心随机研究的初步结果
为了比较干扰素与羟基脲治疗慢性髓性白血病(CML)的效果,从1987年5月1日至1990年7月1日,58例未接受过治疗的慢性髓性白血病患者被随机分为两个治疗组(羟基脲或干扰素),进行了一项开放的多中心研究。50例患者可评价:干扰素组24例,羟基脲组26例。1624例干扰素治疗患者和2326例羟基脲治疗患者获得血液学应答。24例干扰素治疗患者中有8例血液学缓解失败,26例羟基脲治疗患者中有3例血液学缓解失败。4例干扰素治疗失败和1例羟脲治疗失败是由于药物不耐受。1例干扰素治疗患者和3例羟基脲治疗患者出现进展。干扰素组16例患者中有14例和羟基脲组1723例患者继续研究,无进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Preclinical evaluation of polymer-bound doxorubicin Corrections News Introduction Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1